Japan’s contract drug rep ratio rose to 8.7% in FY2024 as the total number of regular reps continued to fall, the Japan Contract Sales Organization Association (JCSOA) reported in June. Amid industry downsizing, the roles and expectations placed on contract…
BUSINESS
Mochida, Meiji Expand Epadel Sales Collab to ASEAN, Taiwan
Mochida Pharmaceutical and Meiji Seika Pharma said on August 30 that they have broadened their marketing collaboration for the high-purity ethyl icosapentate (EPA) agent Epadel S (ethyl icosapentate) to the ASEAN region and Taiwan. The two companies have already tied…
To read the full story
Related Article
- Vietnam Clears Epadel for Import, Launch Planned via Partner: Mochida/Meiji
June 20, 2025
- Mochida Files EPA Agent Epadel in China
July 3, 2024
- Mochida, Meiji Adds China for Epadel Sales Collaboration
April 4, 2024
- Meiji Scoops Up Marketing Rights for Mochida’s Epadel in Vietnam
April 7, 2020
- Epadel to Enter Clinical Study in China: Mochida, Sumitomo Dainippon
July 18, 2018
BUSINESS
- Ashraf Al-Ouf Named President of Bayer Yakuhin and Bayer Holding in Japan
August 8, 2025
- Sumitomo Eyes Conditional Nod for iPS Cell Therapy for Parkinson’s in FY2025
August 8, 2025
- PeptiDream Probes Ex-COO over Unauthorized Provision of Reagents to Academia
August 8, 2025
- Kaken, Astria Ink Japan Deal for Navenibart for HAE Prophylaxis
August 8, 2025
- Ono, Seikagaku Finalize Japan Deal on Osteoarthritis Drug
August 8, 2025
A recent conversation with a US biopharma senior director highlighted a critical talent gap: a strong demand for individuals with strategic management, critical thinking, and advanced business acumen-skills beyond traditional operational excellence. After the conversation, I rushed home and picked…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…